Latest News
News
Great to see our friends at Blueberry Therapeutics achieve this
http://www.blueberrytherapeutics.com/blueberry-therapeutics-limited-closes-10m-funding-to-support-development-of-nanomedicines-portfolio/
Read more >Aptus Clinical delighted by MHRA announcement on CTR
MHRA update on Clinical Trials Regulation Aptus Clinical are delighted at the MHRAs announcement this week that the UK will follow the EU Clinical Trials Regulation (CTR) when it is implemented in 2020. This provides much needed reassurance for us…
Read more >Aptus Clinical enters into a global partnership agreement with Artelo Biosciences
Press Release Artelo Biosciences ENTERS INTO GLOBAL R&D PARTNERSHIP WITH SYNGENE INTERNATIONAL and APTUS CLINICAL for the clinical development of ART27.13 in oncology LA JOLLA, CA – June 5, 2018 – Artelo Biosciences, Inc. (OTCQB: ARTL), a biopharmaceutical company focused…
Read more >CEO gives a talk at the Advanced Therapies & Regenerative Medicine Congress
Aptus Clinical CEO Steve McConchie discusses Aptus Clinical and their role in iMATCH at the World Advanced Therapies & Regenerative Medicine Congress May 2018. https://twitter.com/aptusclinical/status/999983518720712704
Read more >
Aptus Clinical Awarded Part of £7m Government Investment
Manchester-based Aptus Clinical are one of twelve partners receiving government funding to ensure that more patients benefit from a new generation of medicines. Nearly £7m has been awarded to the Innovate Manchester Advanced Therapy Centre Hub (iMATCH) by Innovate UK…
Read more >
Delighted to be part of iMATCH
A recently formed Manchester health consortium, led by The Christie, has been awarded nearly £7 million of funding to ensure more patients benefit from a new generation of disease-fighting drugs for cancer and non-cancer illnesses. Manchester is one of only…
Read more >